The CDK4/6 inhibitor palbociclib exhibited preliminary activity in patients with acral lentiginous melanoma associated with CDK-pathway aberrations, according to results of a small phase II trial that were reported at the 2019 ASCO Annual Meeting.
Updated results from the phase III COLUMBUS trial show continued prolonged progression-free and overall survival with the combination of encorafenib and binimetinib compared with BRAF inhibition alone in patients with advanced/metastatic BRAF V600-mutant melanoma.
Neoadjuvant treatment with the oncolytic immunotherapeutic agent talimogene laherparepvec (T-VEC; Imlygic) led to significant improvement in 1-year recurrence-free survival for patients with resectable advanced melanoma compared with surgery alone.
Five years out, one-third of patients with unresectable or metastatic BRAF V600-mutant melanoma remained alive following treatment with dual targeted therapy with dabrafenib (Tafinlar) plus trametinib (Mekinist), and 1 in 5 remained alive without progression.
Among patients with locally advanced cutaneous squamous cell carcinoma (CSCC) who were enrolled in the pivotal EMPOWER-CSCC-1 phase II study, cemiplimab exhibited substantial antitumor activity and induced durable responses similar to those experienced in patients with metastatic CSCC who were enrolled in the same study.